链接:https://www.fda.gov/media/153409/download 辉瑞递交给FDA的报告链接
请查看第11页报告第三段:
The number of participants in the current clinical development program is too small to detectany potential risks of myocarditis associated with vaccination. Long-term safety ofCOVID-19 vaccine in participants 5 to <12 years of age will be studied in5 post-authorization safety studies, including a 5-year follow-up study to evaluate long termsequelae of post-vaccination myocarditis/pericarditis.
辉瑞公司甚至承认其临床试验志愿者的样本量太小,无法检测5至12岁儿童的心肌炎风险。“新冠疫苗在5至12岁的接种者中的长期安全性将在5项授权后的安全性研究中进行研究,包括一项5年的随访研究,以评估疫苗接种后心肌炎/心包炎的长期后遗症”。 请各位家长知悉此项风险,全面衡量风险与收益,做出选择。
|